<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04256369</url>
  </required_header>
  <id_info>
    <org_study_id>2191316</org_study_id>
    <nct_id>NCT04256369</nct_id>
  </id_info>
  <brief_title>Rate of Termination of Premixed Parenteral Nutrition (PN) in Surgical Patients Secondary to High Serum Electrolytes</brief_title>
  <official_title>Rate of Termination of Commercial Premixed Parenteral Nutrition (PN) in Surgical Patients Secondary to High Serum Electrolyte Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Faisal Specialist Hospital &amp; Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Faisal Specialist Hospital &amp; Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction:&#xD;
&#xD;
      Various commercial premixed parenteral nutrition (PN) solutions have been introduced to&#xD;
      clinical practice in 3-compartment large volume bags. Olimel N9E is the formulary premixed PN&#xD;
      formula at King Faisal Specialist Hospital and Research Centre (KFSH &amp; RC). The commercial&#xD;
      premixed PN was associated with a significant cost reduction compared to the compounded PN,&#xD;
      with lower incidence of infectious complications, compared to the compounded PN formula.&#xD;
      Electrolyte irregularities are commonly encountered with PN use. Patients who develop high&#xD;
      serum potassium, magnesium or phosphate levels while receiving premixed PN are shifted to a&#xD;
      compounded PN with lower electrolyte content. This study aims to describe the incidence of&#xD;
      shifting of premixed PN to a compounded PN secondary to high serum electrolytes in surgical&#xD;
      patients receiving commercial premixed PN.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      This is a prospective, cohort, study, to be conducted at KFSH &amp; RC, Riyadh. This study is&#xD;
      proposed to commence after obtaining the approval of the Research Ethical Committee at KFSH &amp;&#xD;
      RC. Patients enrolment will start after the approval at KFSH &amp; RC, by data collection phase,&#xD;
      that might extend for a suspected 6-month until achieving the target sample size of 55&#xD;
      patients. The analysis phase will follow and elapse for 2 months. This is followed by 2&#xD;
      months to get the initial abstract. All patients will have their potassium, magnesium,&#xD;
      calcium and phosphorus levels assessed daily in the morning for the first 7 days of PN&#xD;
      initiation. After the first week of PN support, according to the routine laboratories,&#xD;
      electrolytes will be assessed at a minimum of three times a week thereafter while on PN.&#xD;
      There will be no extra laboratory work obtained for the study purpose. The incidence of&#xD;
      shifting from premixed PN to compounded PN will be assessed and reported. A description of&#xD;
      the characteristics of patients who develop high serum level of electrolytes will be&#xD;
      undertaken using regression analysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods Study design and centres This is a prospective, cohort, multi-centre study, to be&#xD;
      conducted at King Faisal Specialist Hospital and Research Centre, (KFSH &amp; RC), Riyadh. The&#xD;
      study has been approved by KFSH&amp;RC Office of Research Affairs representing the institutional&#xD;
      review board (IRB).&#xD;
&#xD;
      Subjects:&#xD;
&#xD;
      Sample Size Sample size has been calculated using Raosoft website based on the total surgical&#xD;
      patients who receive PN support on monthly bases, which is 20 patients per month, and the&#xD;
      duration of the data collection is expected to elapse 6 months. This makes the field&#xD;
      population represented by 120 patients. According to a previous study that assessed need for&#xD;
      bolus of electrolytes, 7% of the eligible patients are expected to have the outcome. Allowing&#xD;
      for 5% margin of error and 95% confidence level the target sample size will be 72 patients&#xD;
      from KFSH&amp;RC. Collaborating centers withdrew from this study due to insufficient eligible&#xD;
      patients given the COVID-19 pandemic.&#xD;
&#xD;
      Protocol Surgical patients starting PN will be screened for the inclusion and exclusion&#xD;
      criteria by the investigators of the study. Eligible patients will be asked to sign a consent&#xD;
      form.&#xD;
&#xD;
      All patients will start PN after normalization of the following electrolytes potassium,&#xD;
      magnesium, and phosphorus according to standard. Premixed PN formula, Olimel N9E will be&#xD;
      started at a rate of 45 mL per hour for all patients on day 1 of PN support. After the&#xD;
      routine assessment by pharmacists, the PN rate will be increased at an increment of 10 mL per&#xD;
      hour on daily basis, representing the target goal of protein of 2 gm per kg according to the&#xD;
      ideal body weight (IBW) , is achieved. Patients enrolled in the study will be followed while&#xD;
      on PN support until cessation of PN or after 30 days of support have elapsed.&#xD;
&#xD;
      All patients will get their potassium, magnesium, and phosphorus levels assessed daily in the&#xD;
      morning for the first 7 days of PN initiation. After the first week of PN support,&#xD;
      electrolytes will be assessed at a minimum of three times a week thereafter while on PN. High&#xD;
      electrolyte levels that develop on the following day of their respective low levels and&#xD;
      corrected with bolus will not be considered as induced by PN.&#xD;
&#xD;
      Patients who develop hyperphosphatemia, hypermagnesemia, hyperkalaemia will get their PN&#xD;
      stopped immediately and replaced with dextrose 10% water solution to run at 50 mL per hour&#xD;
      till 21:00.Premixed PN will commence again at the same rate of the corresponding day.&#xD;
      Patients who develop a second episode of any hyperphosphatemia, hypermagnesemia, or&#xD;
      hyperkalaemia on the preceding day obtained from a blood sample will be shifted to the&#xD;
      compounded PN.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of shifting of Olimel N9E premixed formula to compounded PN secondary to the development of elevated electrolyte levels in surgical patients receiving PN.</measure>
    <time_frame>Until cessation of parenteral nutritional support or after 30 days of PN support have elapsed.</time_frame>
    <description>Serum phosphate level of &gt; 1.45 mmol/L, serum potassium level &gt; 5.0 mmol/L, and serum magnesium level &gt; 1.0 mmol/L.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of high serum levels of phosphate, magnesium, calcium, and potassium.</measure>
    <time_frame>Until cessation of parenteral nutritional support or after 30 days of PN support have elapsed</time_frame>
    <description>serum phosphate level of &gt; 1.45 mmol/L, serum potassium level &gt; 5.0 mmol/L, and serum magnesium level &gt; 1.0 mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors associated with the development of hyperphosphatemia</measure>
    <time_frame>Until cessation of parenteral nutritional support or after 30 days of PN support have elapsed</time_frame>
    <description>Serum phosphate level of &gt; 1.45 mmol/L</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">72</enrollment>
  <condition>Hyperphosphatemia</condition>
  <condition>Hyperkalemia</condition>
  <condition>Hypermagnesemia</condition>
  <condition>Hypercalcemia</condition>
  <arm_group>
    <arm_group_label>Primary Cohort</arm_group_label>
    <description>Starting premixed Olimel N9E and follow for electrolyte irregularities.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Parenteral Nutrition (PN) Premixed Olimel N9E</intervention_name>
    <description>Parenteral nutrition</description>
    <arm_group_label>Primary Cohort</arm_group_label>
    <other_name>Olimel N9E</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All adult (≥ 18) patients admitted to King Faisal Specialist Hospital and Research Centre,&#xD;
        Riyadh , under non-cardiac surgical services, whether planned for surgery or to manage a&#xD;
        surgical complication that developed within 30 after surgery, in which parenteral nutrition&#xD;
        is indicated and is the sole source of nutrition.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients admitted under the care of non-cardiac surgical services, whether planned for&#xD;
             surgery or to manage a surgical complications that developed within 30 after surgery.&#xD;
&#xD;
          -  Patients under the care of the following surgical teams: colorectal surgery, oncology&#xD;
             surgery, general surgery, and thoracic surgery.&#xD;
&#xD;
          -  Patients starting PN as a sole source for nutrition with feeding status is nil per os&#xD;
             (NPO)&#xD;
&#xD;
          -  Patients who receive sips of water or oral tablets will be included in this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any degree of renal impairment defined as glomerular filtration rate &lt; 60 mL/min/m2 as&#xD;
             calculated according to the modification of diet in renal disease (MDRD) equation&#xD;
&#xD;
          -  Morbid obesity defined as body mass index (BMI) of &gt; 40 kg/m2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hakeam Hakeam, MS Pharm</last_name>
    <role>Principal Investigator</role>
    <affiliation>King Faisal Specialist Hospital and Research Centre (KFSH&amp;RC)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>King Faisal Specialist Hospital &amp; Research Centre</name>
      <address>
        <city>Riyadh</city>
        <zip>11211</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <reference>
    <citation>Maisonneuve N, Raguso CA, Paoloni-Giacobino A, Mühlebach S, Corriol O, Saubion JL, Hecq JD, Bailly A, Berger M, Pichard C. Parenteral nutrition practices in hospital pharmacies in Switzerland, France, and Belgium. Nutrition. 2004 Jun;20(6):528-35.</citation>
    <PMID>15165615</PMID>
  </reference>
  <reference>
    <citation>Hall JW. Safety, cost, and clinical considerations for the use of premixed parenteral nutrition. Nutr Clin Pract. 2015 Jun;30(3):325-30. doi: 10.1177/0884533615578459. Epub 2015 Apr 10.</citation>
    <PMID>25862011</PMID>
  </reference>
  <reference>
    <citation>DeLegge MH. Parenteral nutrition therapy over the next 5-10 years: where are we heading? JPEN J Parenter Enteral Nutr. 2012 Mar;36(2 Suppl):56S-61S. doi: 10.1177/0148607111435333. Epub 2012 Feb 2.</citation>
    <PMID>22301323</PMID>
  </reference>
  <reference>
    <citation>Pontes-Arruda A, Zaloga G, Wischmeyer P, Turpin R, Liu FX, Mercaldi C. Is there a difference in bloodstream infections in critically ill patients associated with ready-to-use versus compounded parenteral nutrition? Clin Nutr. 2012 Oct;31(5):728-34. doi: 10.1016/j.clnu.2012.03.004. Epub 2012 May 8.</citation>
    <PMID>22572624</PMID>
  </reference>
  <reference>
    <citation>Berlana D, Almendral MA, Abad MR, Fernández A, Torralba A, Cervera-Peris M, Piñeiro G, Romero-Jiménez R, Vázquez A, Ramírez E, Yébenes M, Muñoz Á. Cost, Time, and Error Assessment During Preparation of Parenteral Nutrition: Multichamber Bags Versus Hospital-Compounded Bags. JPEN J Parenter Enteral Nutr. 2019 May;43(4):557-565. doi: 10.1002/jpen.1436. Epub 2018 Aug 29.</citation>
    <PMID>30156305</PMID>
  </reference>
  <reference>
    <citation>Weimann A, Braga M, Carli F, Higashiguchi T, Hübner M, Klek S, Laviano A, Ljungqvist O, Lobo DN, Martindale R, Waitzberg DL, Bischoff SC, Singer P. ESPEN guideline: Clinical nutrition in surgery. Clin Nutr. 2017 Jun;36(3):623-650. doi: 10.1016/j.clnu.2017.02.013. Epub 2017 Mar 7. Review.</citation>
    <PMID>28385477</PMID>
  </reference>
  <reference>
    <citation>Hardy G, Puzovic M. Formulation, stability, and administration of parenteral nutrition with new lipid emulsions. Nutr Clin Pract. 2009 Oct-Nov;24(5):616-25. doi: 10.1177/0884533609342445. Review.</citation>
    <PMID>19841249</PMID>
  </reference>
  <reference>
    <citation>Biesalski HK, Bischoff SC, Boehles HJ, Muehlhoefer A; Working group for developing the guidelines for parenteral nutrition of The German Association for Nutritional Medicine. Water, electrolytes, vitamins and trace elements - Guidelines on Parenteral Nutrition, Chapter 7. Ger Med Sci. 2009 Nov 18;7:Doc21. doi: 10.3205/000080. Review.</citation>
    <PMID>20049067</PMID>
  </reference>
  <reference>
    <citation>Boullata JI, Gilbert K, Sacks G, Labossiere RJ, Crill C, Goday P, Kumpf VJ, Mattox TW, Plogsted S, Holcombe B; American Society for Parenteral and Enteral Nutrition. A.S.P.E.N. clinical guidelines: parenteral nutrition ordering, order review, compounding, labeling, and dispensing. JPEN J Parenter Enteral Nutr. 2014 Mar-Apr;38(3):334-77. doi: 10.1177/0148607114521833. Epub 2014 Feb 14. Review.</citation>
    <PMID>24531708</PMID>
  </reference>
  <reference>
    <citation>Beattie C, Allard J, Raman M. Comparison Between Premixed and Compounded Parenteral Nutrition Solutions in Hospitalized Patients Requiring Parenteral Nutrition. Nutr Clin Pract. 2016 Apr;31(2):229-34. doi: 10.1177/0884533615621046. Epub 2016 Feb 17.</citation>
    <PMID>26888855</PMID>
  </reference>
  <reference>
    <citation>Fantoni D, Shih AC. Perioperative Fluid Therapy. Vet Clin North Am Small Anim Pract. 2017 Mar;47(2):423-434. doi: 10.1016/j.cvsm.2016.11.004. Review.</citation>
    <PMID>28164837</PMID>
  </reference>
  <reference>
    <citation>Peppers MP, Geheb M, Desai T. Endocrine crises. Hypophosphatemia and hyperphosphatemia. Crit Care Clin. 1991 Jan;7(1):201-14. Review.</citation>
    <PMID>2007215</PMID>
  </reference>
  <reference>
    <citation>Vernon WB, Atkins JM, Stewart RD. Hyperphosphatemia from lipid emulsion in a patient on total parenteral nutrition. JPEN J Parenter Enteral Nutr. 1988 Jan-Feb;12(1):84-7.</citation>
    <PMID>3125363</PMID>
  </reference>
  <reference>
    <citation>Nyirenda MJ, Tang JI, Padfield PL, Seckl JR. Hyperkalaemia. BMJ. 2009 Oct 23;339:b4114. doi: 10.1136/bmj.b4114. Review.</citation>
    <PMID>19854840</PMID>
  </reference>
  <reference>
    <citation>Mendoza J, Legido J, Rubio S, Gisbert JP. Systematic review: the adverse effects of sodium phosphate enema. Aliment Pharmacol Ther. 2007 Jul 1;26(1):9-20. Review.</citation>
    <PMID>17555417</PMID>
  </reference>
  <reference>
    <citation>Leaf DE, Wolf M. A physiologic-based approach to the evaluation of a patient with hyperphosphatemia. Am J Kidney Dis. 2013 Feb;61(2):330-6. doi: 10.1053/j.ajkd.2012.06.026. Epub 2012 Aug 30.</citation>
    <PMID>22938849</PMID>
  </reference>
  <reference>
    <citation>Eliacik E, Yildirim T, Sahin U, Kizilarslanoglu C, Tapan U, Aybal-Kutlugun A, Hascelik G, Arici M. Potassium abnormalities in current clinical practice: frequency, causes, severity and management. Med Princ Pract. 2015;24(3):271-5. doi: 10.1159/000376580. Epub 2015 Mar 11.</citation>
    <PMID>25766276</PMID>
  </reference>
  <reference>
    <citation>Busch RA, Curtis CS, Leverson GE, Kudsk KA. Use of Piggyback Electrolytes for Patients Receiving Individually Prescribed vs Premixed Parenteral Nutrition. JPEN J Parenter Enteral Nutr. 2015 Jul;39(5):586-90. doi: 10.1177/0148607113518583. Epub 2014 Jan 3.</citation>
    <PMID>24390715</PMID>
  </reference>
  <reference>
    <citation>Kelly DG. Guidelines and available products for parenteral vitamins and trace elements. JPEN J Parenter Enteral Nutr. 2002 Sep-Oct;26(5 Suppl):S34-6. Review.</citation>
    <PMID>12216718</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 3, 2020</study_first_submitted>
  <study_first_submitted_qc>February 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>October 23, 2021</last_update_submitted>
  <last_update_submitted_qc>October 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Faisal Specialist Hospital &amp; Research Center</investigator_affiliation>
    <investigator_full_name>Hakeam Abdulaziz Hakeam</investigator_full_name>
    <investigator_title>Clinical Pharmacy Specialist, Surgery. Pharmaceutical Care Division, King Faisal Specialist Hospital &amp; Research Centre. Adjunct Assistant Clinical Professor College of Medicine, Alfaisal University.</investigator_title>
  </responsible_party>
  <keyword>Parenteral Nutrition</keyword>
  <keyword>Hyperkalemia</keyword>
  <keyword>Hypermagnesemia</keyword>
  <keyword>Hyperphosphatemia</keyword>
  <keyword>Hypercalcemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperphosphatemia</mesh_term>
    <mesh_term>Hyperkalemia</mesh_term>
    <mesh_term>Hypercalcemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>On publication, according to the journal requirements.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After November 2020.</ipd_time_frame>
    <ipd_access_criteria>Pending</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

